Hospital
Lodi Community Hospital
Lodi Community Hospital was paid $17.53M by Medicaid between Jan 2018 and Dec 2024, across 96 billing codes. Its largest line is 99283, emergency room visit (moderate) — 20% of everything it billed.
33Billing provider infoLODI COMMUNITY HOSPITAL
LODI, OH 44254
LODI, OH 44254
33aNPI1801807870assigned 08/11/2006
33bProvider typeCritical Access Hospital
28Total paid$17.53M
24GClaims73,196
24DCodes billed96
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Critical Access Hospital providers in Ohio
Rank by total paid#2 of 26
Median peer was paid$5.33M
This provider vs. median3.3×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official LARAWAY, DENNIS controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 4,872 | $229K | |
| 2019 | 5,808 | $281K | |
| 2020 | 3,649 | $506K | |
| 2021 | 5,119 | $1.09M | |
| 2022 | 5,228 | $1.74M | |
| 2023 | 26,642 | $7.29M | |
| 2024incomplete | 21,878 | $6.40M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 20% | 7,250 | 6,628 | $3.54M |
| 96361 | Intravenous infusion, hydration; each additional hour | 18% | 1,760 | 1,277 | $3.15M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 16% | 4,355 | 3,527 | $2.83M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 13% | 3,622 | 3,125 | $2.31M |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 7.1% | 1,910 | 1,615 | $1.25M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 4.8% | 660 | 503 | $847K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 3.5% | 1,582 | 522 | $605K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 2.8% | 500 | 318 | $497K |
| 70450 | Computed tomography, head or brain; without contrast material | 2.2% | 394 | 301 | $394K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.0% | 434 | 381 | $346K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 1.7% | 732 | 582 | $304K |
| 80053 | Comprehensive metabolic panel | 1.2% | 4,570 | 3,682 | $203K |
84 more codes
| 96127 | <1% | 274 | $160K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 128 | $132K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 1,067 | $90K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 181 | $90K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 80 | $75K |
| 36415 | Collection of venous blood by venipuncture | <1% | 9,168 | $70K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 856 | $69K |
| 80061 | Lipid panel | <1% | 929 | $66K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 463 | $62K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 5,572 | $51K |
| 85027 | <1% | 1,565 | $49K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 251 | $45K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 102 | $30K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 1,702 | $23K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 1,932 | $21K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 160 | $20K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 504 | $19K |
| 84439 | <1% | 130 | $13K | |
| 73630 | <1% | 154 | $12K | |
| 84702 | <1% | 179 | $12K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 13 | $11K |
| 83735 | <1% | 907 | $11K | |
| 84484 | <1% | 2,015 | $11K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 64 | $10K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 517 | $10K |
| 81001 | <1% | 2,720 | $10K | |
| 82607 | <1% | 134 | $9K | |
| 83690 | <1% | 1,032 | $7K | |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 32 | $7K |
| 83540 | <1% | 118 | $6K | |
| 82728 | <1% | 60 | $6K | |
| 71045 | Radiologic examination, chest; single view | <1% | 1,054 | $6K |
| 82805 | <1% | 48 | $5K | |
| 83550 | <1% | 115 | $5K | |
| 85610 | <1% | 392 | $5K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 2,089 | $4K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 986 | $4K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 278 | $2K |
| 83880 | <1% | 122 | $2K | |
| 73030 | <1% | 20 | $2K | |
| 87400 | <1% | 195 | $2K | |
| 83605 | <1% | 711 | $2K | |
| 73130 | <1% | 29 | $2K | |
| 87077 | <1% | 114 | $2K | |
| 82746 | <1% | 29 | $1K | |
| 80076 | <1% | 22 | $1K | |
| 82570 | <1% | 49 | $1K | |
| 86140 | <1% | 30 | $1K | |
| 73610 | <1% | 52 | $1K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 342 | $1K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 18 | $993.82 |
| 82043 | <1% | 31 | $887.94 | |
| 81025 | <1% | 681 | $692.41 | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 16 | $641.00 |
| 87186 | <1% | 37 | $538.43 | |
| 84132 | <1% | 100 | $533.46 | |
| 85652 | <1% | 15 | $416.19 | |
| 85379 | <1% | 32 | $394.99 | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 167 | $279.22 |
| 82330 | <1% | 56 | $157.26 | |
| 82947 | <1% | 56 | $125.55 | |
| 81003 | <1% | 67 | $99.00 | |
| 82962 | <1% | 42 | $57.00 | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 546 | $44.20 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 194 | $36.43 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 1,007 | $28.51 |
| 87081 | <1% | 76 | $17.11 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 830 | $8.65 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 1,048 | $0.34 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | 0% | 26 | $0.00 |
| 85018 | 0% | 49 | $0.00 | |
| 82077 | 0% | 55 | $0.00 | |
| 87040 | 0% | 119 | $0.00 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | 0% | 29 | $0.00 |
| 96376 | 0% | 38 | $0.00 | |
| 94760 | 0% | 24 | $0.00 | |
| 83050 | 0% | 47 | $0.00 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | 0% | 29 | $0.00 |
| 84703 | 0% | 57 | $0.00 | |
| 82375 | 0% | 46 | $0.00 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 0% | 113 | $0.00 |
| 84295 | 0% | 52 | $0.00 | |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | 0% | 22 | $0.00 |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | 0% | 16 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialLARAWAY, DENNIS (EXECUTIVE VP CHIEF FINANCE OFFICER)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.